Uniqure (NASDAQ:QURE) had its price objective raised by stock analysts at SunTrust Banks to $76.00 in a report issued on Tuesday, May 7th, The Fly reports. The firm currently has a “buy” rating on the biotechnology company’s stock. SunTrust Banks’ price target suggests a potential upside of 25.77% from the stock’s previous close.
QURE has been the topic of a number of other research reports. BidaskClub upgraded Uniqure from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 13th. Wells Fargo & Co upped their price target on Uniqure from $65.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, March 15th. Cantor Fitzgerald restated a “buy” rating and issued a $81.00 price target on shares of Uniqure in a report on Thursday, March 7th. Zacks Investment Research cut Uniqure from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 6th. Finally, Chardan Capital increased their target price on Uniqure from $70.00 to $100.00 and gave the company a “buy” rating in a report on Monday, March 4th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Uniqure currently has an average rating of “Buy” and a consensus target price of $75.82.
Shares of NASDAQ:QURE traded down $1.36 on Tuesday, hitting $60.43. 388,800 shares of the company’s stock were exchanged, compared to its average volume of 479,558. The company has a debt-to-equity ratio of 0.38, a quick ratio of 9.51 and a current ratio of 9.51. The stock has a market cap of $2.38 billion, a P/E ratio of -25.82 and a beta of 0.99. Uniqure has a 1-year low of $21.98 and a 1-year high of $69.60.
Uniqure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($0.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.03). The company had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $2.00 million. Uniqure had a negative net margin of 1,032.06% and a negative return on equity of 48.90%. On average, equities research analysts predict that Uniqure will post -3.07 EPS for the current year.
In other Uniqure news, insider Christian Klemt sold 1,546 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total value of $88,400.28. Following the transaction, the insider now directly owns 54,539 shares of the company’s stock, valued at $3,118,540.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Philip Astley-Sparke sold 6,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $59.84, for a total value of $359,040.00. Following the completion of the transaction, the director now directly owns 19,272 shares in the company, valued at $1,153,236.48. The disclosure for this sale can be found here. Insiders sold a total of 82,922 shares of company stock worth $5,223,849 over the last ninety days. Corporate insiders own 2.91% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Harvest Group Wealth Management LLC acquired a new position in Uniqure in the first quarter worth about $26,000. Legal & General Group Plc boosted its stake in Uniqure by 264.2% in the fourth quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 700 shares during the period. Kore Private Wealth LLC acquired a new position in Uniqure in the first quarter valued at approximately $30,000. Pearl River Capital LLC acquired a new position in Uniqure in the first quarter valued at approximately $32,000. Finally, SEI Investments Co acquired a new position in Uniqure in the first quarter valued at approximately $35,000. Institutional investors and hedge funds own 60.12% of the company’s stock.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
See Also: What is an SEC Filing?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.